Habermehl P, Lignitz A, Knuf M, Schmitt H J, Slaoui M, Zepp F
Pediatric Immunology and Infectious Diseases, Johannes-Gutenberg-University, Mainz, Germany.
Vaccine. 1999 Feb 26;17(7-8):669-74. doi: 10.1016/s0264-410x(98)00249-7.
Chickenpox and zoster are an important cause of morbidity among children and adults. The ability of a new, thermostable vaccine to induce varicella-zoster-virus (VZV)-specific humoral and cell mediated immunity when given simultaneously with diphtheria-tetanus-acellular pertussis vaccine (DTaP) as a booster dose in the second year of life was investigated.
A new, temperature stable varicella vaccine (OKA-strain, SB-Biologicals, Rixensart, Belgium) was given simultaneously with a booster dose of DTaP vaccine. VZV-specific humoral and cell-mediated immunity was studied in the first 27 out of 232 vaccinated children at 16-28 months of age, from blood samples drawn just before and six weeks after vaccination. VZV-specific antibody response, T-cell proliferation, cytokine production and expression of activation markers (CD25, HLADR) on T-cells were analyzed.
Vaccination resulted in a significant rise of VZV-specific serum IgG titers and in a strong VZV-specific T-cell response in all vaccinated infants. Analysis of the expression of activation marker revealed activation of both CD4+-T-helper- and CD8+-T-cells.
The varicella vaccine given simultaneously with DTaP produced strong B- and T-cell responses alike. This is the first report to show that CMI to VZV is conferred to young children by vaccination with a temperature stable VZV vaccine.
水痘和带状疱疹是儿童及成人发病的重要原因。研究了一种新型热稳定疫苗在生命第二年作为加强剂量与白喉-破伤风-无细胞百日咳疫苗（DTaP）同时接种时，诱导水痘-带状疱疹病毒（VZV）特异性体液免疫和细胞介导免疫的能力。
一种新型温度稳定水痘疫苗（OKA株，SB生物制品公司，比利时里克森萨特）与一剂DTaP疫苗加强剂同时接种。在232名接种疫苗儿童中的前27名16 - 28月龄儿童中，研究VZV特异性体液免疫和细胞介导免疫，在接种前和接种后六周采集血样。分析VZV特异性抗体反应、T细胞增殖、细胞因子产生以及T细胞上激活标志物（CD25、HLADR）的表达。
接种疫苗导致所有接种婴儿的VZV特异性血清IgG滴度显著升高以及强烈的VZV特异性T细胞反应。激活标志物表达分析显示CD4 +辅助性T细胞和CD8 + T细胞均被激活。
与DTaP同时接种的水痘疫苗产生了相似的强烈B细胞和T细胞反应。这是第一份表明通过接种温度稳定的VZV疫苗可使幼儿获得VZV细胞介导免疫的报告。
